Bromocriptine, a dopamine (D2) receptor agonist, used alone and in combination with glipizide in sub-Therapeutic doses to ameliorate hyperglycaemia

Journal of Clinical and Diagnostic Research

Volumn 7, Issue 9, 2013, Pages 1904-1907

  Harish Kumar, V S ^a   Vinutha, M B ^a   Pradeep, A N ^a   Aithal, Sathisha ^a   Reddy Baleed, Sindhura ^a   Patil, Umakant N ^a  

^a S S Institute of Medical Sciences   (India)

Author keywords

Alloxan; Anti hyperglycaemic; Bromocriptine; Glipizide

Indexed keywords

BROMOCRIPTINE; GLIPIZIDE; GLUCOSE;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; MALE; MONOTHERAPY; NONHUMAN; RAT;

EID: 84883850744     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2013/5803.3347     Document Type: Article

References (20)

1. Rajiv Mahajan. Bromocriptine Mesylate: FDA-approved novel treatment for type-2 diabetes. Indian J Pharmacol. 2009 August; 41(4): 197-98.
2. Beth A Musil, Pharm D, CDE, Denise L Walbrandt Pigarelli, PharmD, BC-ADM. New Drugs for Glycemic Control in Type 2 Diabetes Mellitus. Recently-approved and pipeline drugs for treatment of type 2 diabetes. JPSW. 2010 Sept/Oct; 18.
3. Petra Kok, Ferdinand Roelfsema, Marijke Frolich, Johannes van Pelt, Marcel P M Stokkel, A Edo Meinders, Hanno Pijl. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Am J Physiol Endocrinol Metab. 2006 June; 291:E1038-E43.
4. H Gerhard Vogel, Wolfgang H Vogel, Bernward A Scholkens, Jurgen Sandow Gunter Muller, Wolfgang F Vogel. Drug Discovery and Evaluation Pharmacological Assays. Springer-Verlag Berlag Heidelberg, 2nd Edition. 2002; 950.
5. Gupta SK. Drug Screening Methods. Jaypee publication. 1st edition; 2004; 307.
6. A Mishra, R Kumari, PN Murthy, PP Dash. Influence of Atorvastatin on the pharmacodynamics of Glipizide in normal and diabetic rats. Der Pharma Chemica 2010; 2 (2): 101-04.
7. Dolly Jaiswal, Prashant Kumar Rai, Geeta Watal. Antidiabetic effect of withania coagulans in experimental rats. Indian Journal of Clinical Biochemistry 2009; 24 (1): 88-93.
8. A Ribeiro-de-Oliveira Jr, RM Guerra, RB Foscolo, U Marubayashi, AM Reis, CC Coimbra. Effects of chronic bromocriptine (CB-154) treatment on the plasma glucose and insulin secretion response to neurocytoglucopenia in rats. J Endocrinol. 1999 Aug; 162 (2):237-42.
9. Gosh M N. Fundamentals of Experimental Pharmacology, Hilton and Company, 3 rd edition; 2005; 15.
10. Harish Kumar VS, Sindhu NR, Rajashri S Patil, Umakant Patil. Anti-hyperglycemic activity of simvastatin alone (therapeutic dose) and combination of simvastatin and glipizide (sub therapeutic doses) on alloxan induced hyperglycemia in albino rats. Int J Pharm Sci Res. 2012; 3(11):4398-403.
11. Ralph A De Fronzo. Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes. Diabetes Care, 2011 April;34(4):789-94.
12. Scranton R, Cincotta A. Bromocriptine-unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2010 Feb; 11(2):269-79.
13. Masaharu Ito, Kohei Matsuura, Akira Aiko, Kazuo Matsui, Toshihiro Yoshimura, Hitoshi Okamura. Successful Treatment with Bromocriptine of Hypertension Associated with Polycystic Ovarian Disease. Acta Obstetricia et Gynecologica Scandinavica, 1987; 66(3): 279-82.
14. Anthony H Cincotta, Albert H Meier. Bromocriptine (Ergoset) Reduces Body Weight and Improves Glucose Tolerance in Obese Subjects. Diabetes Care, 1996 June;19 (6): 667-70.
15. Zhang Y, Scislowski PW, Prevelige R, Phaneuf S, Cincotta AH. Bromocriptine/ SKF38393 treatment ameliorates dyslipidemia in ob/ob mice. Metabolism,1999 Aug;48(8):1033-40.
16. J Michael gaziano, Anthony H Cincotta, Christopher M. Oconnor, Michael Ezrokhi, Dean Rutty, Z J Ma, Richard E Scranton. Randomized Clinical Trial of QuickRelease Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes. Diabetes Care, 2010; 33:1503-08.
17. Kerr JL, Timpe EM, Petkewicz KA. Bromocriptine mesylate for glycemic management in type2 Diabetes Mellitus. Ann Pharmacother, 2010 Nov; 44(11): 1777-85.
18. Joseph L Evans, Robert J Rushakoff. Oral Pharmacological Agents for Type 2 Diabetes. ENDOTEXT; 2010 December.
19. Brunton LL, Lazo JS, Parker KL, Eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edition, Mc Graw Hill Publications, New York, USA, 2005;1500.
20. H J van der Steeg, H J T Coelingh Bennink. Bromocriptine for induction of ovulation in normoprolactinaemic post-pill anovulation. The Lancet, 1977 March 5; 309(8010):502-04.